Jubilant Organosys bags new contracts worth $92 mn for 2008
Jubilant Organosys Ltd has announced new contracts worth $92 million for its proprietary products and exclusive synthesis segment for 2008.
By INDIATIMES NEWS NETWORK |
MUMBAI: Jubilant Organosys Ltd has announced new contracts worth $92 million for its proprietary products and exclusive synthesis segment for 2008.
Given Jubilant's geographical focus on the regulated markets, a large percentage of these contracts are realisable from the US, Europe and Japan. Outside the geographical region of the regulated markets, China is a major market for Jubilant. Jubilant's order book for the calendar year stands augmented by 50 per cent with the addition of these contracts.
The new contracts have been signed with prominent international pharma and other life science companies.
In addition to these annual contracts, the company also executes half yearly, quarterly and monthly contracts and spot sales.
Commenting on the development, Shyam S Bhartia, Chairman and Managing Director and Han S Bhartia, Co-Chairman & Managing Director of Jubilant Organosys said: "the momentum in CRAMS related outsourcing is accelerating. The signing of the recent agreements is expected to translate into considerable improved performance in the key pharma and life sciences products segment during the calendar year 2008".
Given Jubilant's geographical focus on the regulated markets, a large percentage of these contracts are realisable from the US, Europe and Japan. Outside the geographical region of the regulated markets, China is a major market for Jubilant. Jubilant's order book for the calendar year stands augmented by 50 per cent with the addition of these contracts.
The new contracts have been signed with prominent international pharma and other life science companies.
In addition to these annual contracts, the company also executes half yearly, quarterly and monthly contracts and spot sales.
Commenting on the development, Shyam S Bhartia, Chairman and Managing Director and Han S Bhartia, Co-Chairman & Managing Director of Jubilant Organosys said: "the momentum in CRAMS related outsourcing is accelerating. The signing of the recent agreements is expected to translate into considerable improved performance in the key pharma and life sciences products segment during the calendar year 2008".
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
